Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Huzhou
Clinical trial register · China

Clinical Trials in Huzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19212 matching records held by the registry are in this view. Synced 10 Nov 2026, 03:17 UTC
19212
Studies in scope
all four open statuses
11805
Recruiting now
open to new participants
2029
Lead sponsors
across recruiting studies
Top sites
Beijing 5582 Shanghai 3880 Guangzhou 3354 Hangzhou 1824 Wuhan 1342
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine15 Eli Lilly and Company6 Yu jiren3 AstraZeneca2 The Affiliated People's Hospital of Ningbo University2
Site location
Beijing5582 Shanghai3880 Guangzhou3354 Hangzhou1824 Wuhan1342
All 625 locations
Target enrolment
to

Trials with a site in Huzhou

41 of 19212 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.
Phase 1
88
Changsha, Xi'an, Shanghai, Huzhou
2026-11-15
Recruiting
Capital Medical University
Phase 2
204
Anyang, Beijing, Huzhou, Jiuquan, Lishui, Shangqiu, Suzhou, Taizhou
2026-09-06
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2/3
150
Nanning, Hangzhou, Huzhou, Jiaxing, Ningbo, Taizhou, Beijing
2026-08-27
Recruiting
AstraZeneca
Phase 3
500
Beijing, Changchun, Chengdu, Guangzhou, Huzhou, Nanjing, Ningbo
2026-08-24
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
630
Guangzhou, Wuhan, Nanchang, Shanghai, Chengdu, Hangzhou, Huzhou, Jiaxing
2026-07-01
Active, closed
Boehringer Ingelheim
Phase 2
344
Huzhou, Jinan, Luoyang, Nanjing, Ningbo, Qinhuangdao, Tianjin, Yichang
2026-06-30
Recruiting
IASO-782 in Systemic Lupus Erythematosus
NCT07483346SLE - Systemic Lupus Erythematosus
DrugIASO-782
Shanghai IASO Biotechnology Co., Ltd
Phase 1
20
Hangzhou, Huzhou, Jiaxing
2026-05-26
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
264
Fuzhou, Hangzhou, Huzhou, Jinhua, Ningbo, Wenzhou
2026-05-07
Recruiting
Eli Lilly and Company
Phase 2
531
Binzhou, Chengdu, Guangzhou, Hangzhou, Hengyang, Huizhou, Huzhou, Meihekou
2026-05-06
Recruiting
Novo Nordisk A/S
Phase 3
300
Beijing, Nanjing, Suzhou, Zhenjiang, Huzhou
2026-05-05
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
118
Hangzhou, Fuzhou, Huzhou, Jinhua, Ningbo, Wenzhou
2026-05-01
Not yet open
Effect of taVNS on Perioperative Anxiety in Major Abdominal Surgery
NCT07495163Perioperative Anxiety, Major Abdominal Surgery
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
282
Huzhou, Jiaxing, Meicheng, Hangzhou
2026-05-01
Recruiting
Eli Lilly and Company
Phase 2
342
Binzhou, Chengdu, Guangzhou, Hangzhou, Hengyang, Huizhou, Huzhou, Meihekou
2026-04-29
Active, closed
Capital Medical University
Phase 1
92
Zhangzhou, Jiuquan, Yulin, Shangqiu, Xuzhou, Beijing, Zibo, Huzhou
2026-04-28
Recruiting
Women's Hospital School Of Medicine Zhejiang University
Observational
1,000
Hangzhou, Huzhou, Quzhou, Shaoxing
2026-03-12
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
528
Shanghai, Taiyuan, Hangzhou, Huzhou, Jinhua, Ningbo, Shanhu
2026-02-23
Recruiting
Eli Lilly and Company
Phase 3
900
Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Hefei, Huzhou
2026-02-10
Recruiting
Sir Run Run Shaw Hospital
Phase 4
846
Hangzhou, Huzhou, Ningbo
2026-02-09
Recruiting
Eli Lilly and Company
Phase 3
1,000
Beijing, Changsha, Chaohu, Chengdu, Guangzhou, Haidian District, Hefei, Huzhou
2026-02-09
Recruiting
A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease
NCT07493603Coronary Heart Disease, Coronary Artery Disease, Atheroscleroses
Xia Liang
Phase 1/2
30
Huzhou
2026-01-16
Recruiting
Eli Lilly and Company
Phase 2
400
Changsha, Hangzhou, Huzhou, Jinan, Shanghai, Shijiazhuang, Tianjin, Xiamen
2025-11-24
Recruiting
AstraZeneca
Observational
200
Beijing, Cangzhou, Dongguan, Fuzhou, Guangzhou, Huzhou, Jinan, Nanjing
2025-11-17
Recruiting
Eli Lilly and Company
Phase 3
1,100
Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Huzhou
2025-10-15
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
214
Hangzhou, Huzhou, Jinhua, Yueqing, Zhoushan
2025-07-14
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
51
Hangzhou, Dongyang, Huzhou, Jiaxing, Lishui, Ningbo, Quzhou, Shaoxing
2025-03-11
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
38
Yangzhou, Shanghai, Hangzhou, Huzhou, Jiaxing, Ningbo, Wenzhou
2025-01-06
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
100
Beijing, Chongqing, Guangzhou, Wuhan, Xi’an, Chengdu, Hangzhou, Huzhou
2024-09-21
Recruiting
The Affiliated People's Hospital of Ningbo University
Phase 3
99
Dongyang, Hangzhou, Huzhou, Jiaxing, Jinhua, Lishui, Ningbo, Shaoxing
2024-08-01
Recruiting
The Affiliated People's Hospital of Ningbo University
Phase 3
99
Dongyang, Hangzhou, Huzhou, Jiaxing, Jinhua, Lishui, Ningbo, Shaoxing
2024-08
Recruiting
Zhejiang Provincial People's Hospital
Phase 4
450
Hangzhou, Huzhou, Taizhou, Zhoushan
2024-06-16
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
216
Huzhou, Lishui, Meicheng, Ningbo, Shaoxing, Taizhou
2024-05-31
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,942
Beijing, Changsha, Chongqing, Ganzhou, Guangdong, Hangzhou, Huzhou, Jinan
2024-03-13
Recruiting
First Affiliated Hospital of Zhejiang University
Observational
2,000
Hangzhou, Huzhou, Jiaxing, Lanxi, Lishui, Pinghu, Taizhou, Wenzhou
2023-09-25
Not yet open
Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05970627Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Epstein-Barr Virus-Associated Gastric Carcinoma
DrugsToripalimab·Oxaliplatin
Yu jiren
Phase 2
30
Hangzhou, Huzhou, Lishui, Ningbo, Taizhou
2023-07-28
Recruiting
Sir Run Run Shaw Hospital
Not applicable
422
Hangzhou, Huzhou, Jinhua, Lishui, Ningbo, Quzhou, Shaoxing, Taizhou
2023-07-01
Recruiting
Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05729646Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Mismatch Repair Deficiency
DrugsToripalimab·Oxaliplatin
Yu jiren
Phase 2
90
Hangzhou, Huzhou, Lishui, Ningbo, Taizhou
2023-05-31
Active, closed
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05715931Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, HER2-positive Gastric Cancer
DrugsFLOT·Trastuzumab·Toripalimab
Yu jiren
Phase 2
30
Hangzhou, Huzhou, Lishui, Ningbo, Taizhou
2023-05-30
Not yet open
Effect of Incentive Integrated E-IBD Chronic Disease Management Model on the Quality of Life in IBD Patients
NCT05719766Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
200
Hangzhou, Huzhou, Shanghai, Shaoxing
2023-04-01
Recruiting
Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases
NCT05742425Unresectable Colon Cancer Peritoneal Metastases, PMMR/Ras/BRAF Wild-type
DrugSerplulimab
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
30
Huzhou
2023-03
Active, closed
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
NCT05685238Haemophilia A, Haemophilia A With Inhibitors
Novo Nordisk A/S
Phase 3
451
Beijing, Guangzhou, Wuhan, Changsha, Jinan, Chengdu, Tianjin, Huzhou
2023-02-13
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,872
Hangzhou, Beijing, Guangdong, Huzhou, Jinan, Jinhua, Kunming, Nanchang
2020-05-29
Rows per page Showing 1–41 of 41
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 November 2026. https://priyalifescience.com/clinical-trials-china/city/huzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,212 studies in total at the last sync on 10 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 41 of those studies with a site in Huzhou.

How many clinical trials are recruiting in Huzhou?

27 of the 41 studies on this page are recruiting new participants as of the 10 Nov 2026, 03:17 UTC sync. A further 8 have not yet opened recruitment, 6 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Huzhou), 41 studies
PhaseStudiesRecruitingShare
Phase 211826.8%
Not applicable9122%
Phase 38719.5%
Phase 45512.2%
Observational337.3%
Phase 1317.3%
Phase 1/2112.4%
Phase 2/3112.4%

Most active sponsors

Lead sponsors with the most studies (Huzhou)
Lead sponsorStudiesRecruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine157
Eli Lilly and Company66
Yu jiren31
AstraZeneca22
Capital Medical University21
Novo Nordisk A/S21
Sir Run Run Shaw Hospital22
The Affiliated People's Hospital of Ningbo University22
Boehringer Ingelheim10
First Affiliated Hospital of Zhejiang University11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.